The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preliminary updated results of a phase I/II trial using trimodality therapy in patients with post-prostatectomy high-risk pathologic (p) T2-3N0M0 prostate cancer.
Parvesh Kumar
No relevant relationships to disclose
Peter J. Van Veldhuizen
No relevant relationships to disclose
Mark Thompson
No relevant relationships to disclose
Xinglei Shen
No relevant relationships to disclose
James Coster
No relevant relationships to disclose
Jacek Pinski
No relevant relationships to disclose